



## IBA – ACQUISITION OF OWN SHARES

Immediate Release – April 15<sup>th</sup>, 2021

**Louvain-la-Neuve, Belgium, April 15<sup>th</sup>, 2021** - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on January 12<sup>th</sup>, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 357.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until May 31<sup>st</sup>, 2021, effective as from January 13<sup>th</sup>, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 19.585 IBA shares on Euronext Brussels in the period from April 9<sup>th</sup>, 2021 up to and including April 15<sup>th</sup>, 2021, as follows:

Trade date	Shares purchased	Average price	Min price	Max price	Buyback amount
09-04-21	3.862	17,77 €	17,14 €	18,24 €	68.631,99 €
12-04-21	6.000	17,79 €	17,60 €	18,20 €	106.716,00 €
13-04-21	2.201	17,96 €	17,60 €	18,08 €	39.527,32 €
14-04-21	4.714	17,92 €	17,72 €	18,18 €	84.481,01 €
15-04-21	2.808	17,94 €	17,70 €	18,00 €	50.373,84 €
<b>TOTAL</b>	<b>19.585</b>	<b>17,86 €</b>	<b>17,14 €</b>	<b>18,24 €</b>	<b>349.730,15 €</b>

The total number of shares purchased under this program therefore amounts to 261.429. As a result, IBA SA currently holds 735.650 treasury shares (directly and indirectly through its subsidiary IBA Investments SCRL), representing 2,44% of its share capital.

### About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at [www.iba-worldwide.com](http://www.iba-worldwide.com)

## Press release

Inside / regulated information



### Contact person

**IBA**

Christian Matton,  
Chief Legal Officer

[shareholderrelations@iba-group.com](mailto:shareholderrelations@iba-group.com)